- Home
- BTMD vs CDTX Comparison
BTMD vs CDTX Comparison
Compare BTMD & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- CDTX
- Stock Information
- Founded
- BTMD 2012
- CDTX 2012
- Country
- BTMD United States
- CDTX United States
- Employees
- BTMD N/A
- CDTX N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTMD Health Care
- CDTX Health Care
- Exchange
- BTMD Nasdaq
- CDTX Nasdaq
- Market Cap
- BTMD 136.0M
- CDTX 259.0M
- IPO Year
- BTMD N/A
- CDTX 2015
- Fundamental
- Price
- BTMD $3.07
- CDTX $22.36
- Analyst Decision
- BTMD Strong Buy
- CDTX Strong Buy
- Analyst Count
- BTMD 1
- CDTX 8
- Target Price
- BTMD $8.00
- CDTX $38.00
- AVG Volume (30 Days)
- BTMD 220.4K
- CDTX 102.8K
- Earning Date
- BTMD 03-12-2025
- CDTX 03-06-2025
- Dividend Yield
- BTMD N/A
- CDTX N/A
- EPS Growth
- BTMD N/A
- CDTX N/A
- EPS
- BTMD 0.09
- CDTX N/A
- Revenue
- BTMD $197,191,000.00
- CDTX $1,275,000.00
- Revenue This Year
- BTMD $17.51
- CDTX N/A
- Revenue Next Year
- BTMD $15.84
- CDTX N/A
- P/E Ratio
- BTMD $34.33
- CDTX N/A
- Revenue Growth
- BTMD 6.38
- CDTX N/A
- 52 Week Low
- BTMD $3.04
- CDTX $10.00
- 52 Week High
- BTMD $8.44
- CDTX $28.42
- Technical
- Relative Strength Index (RSI)
- BTMD 22.01
- CDTX 49.66
- Support Level
- BTMD $4.03
- CDTX $20.15
- Resistance Level
- BTMD $4.23
- CDTX $23.66
- Average True Range (ATR)
- BTMD 0.27
- CDTX 1.85
- MACD
- BTMD -0.05
- CDTX -0.14
- Stochastic Oscillator
- BTMD 1.62
- CDTX 41.28
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.